rs1800961 — HNF4A Thr130Ile

HNF4A Thr130Ile — A Hepatocyte Switch With Metabolic Consequences

HNF4A¹¹ HNF4A
Hepatocyte Nuclear Factor 4-Alpha: a master transcription factor that controls hundreds of target genes in the liver, pancreatic beta cells, kidney, and intestine. It sits at the apex of the MODY transcription factor cascade, directly activating HNF1A expression. The Thr130Ile variant (T130I) substitutes threonine for isoleucine at position 130 in the DNA-binding domain — a domain so conserved it is essentially identical across vertebrates. The result is a partial, tissue-selective loss of transcriptional activity that affects the liver more than the pancreas, tilting the metabolic balance toward insulin resistance and dyslipidemia in T allele carriers.

The Mechanism

The p.Thr130Ile substitution falls within the DNA-binding domain of HNF4A. Zhu et al. 2003²² Zhu et al. 2003
Zhu Q et al. T130I mutation in HNF-4alpha gene is a loss-of-function mutation in hepatocytes and is associated with late-onset Type 2 diabetes mellitus in Japanese subjects. Diabetologia, 2003 demonstrated that T130I retains normal transcriptional activity in HeLa cells and MIN6 beta-cell-like cells, but shows 27–78% of wild-type activity in HepG2 hepatoma cells and primary cultured mouse hepatocytes. The functional impairment is therefore hepatocyte-specific, not pancreatic — a key distinction from the truly pathogenic MODY1 nonsense variants (e.g. rs137853334, p.Gln277Ter) that ablate activity in all tissues.

In hepatocytes, HNF4A normally drives expression of genes controlling [gluconeogenesis | the production of glucose from non-carbohydrate sources in the fasting state], lipid metabolism (ApoAII, ApoB, ApoCI/II, CETP), and bile acid synthesis. Partial loss of HNF4A activity in the liver disrupts these programs, producing the clinical signature seen in T130I carriers: elevated fasting glucose, insulin resistance, hypertriglyceridemia, and reduced HDL-cholesterol.

The Evidence

The largest analysis of T130I and type 2 diabetes comes from a meta-analysis by Jafar-Mohammadi et al. 2011³³ meta-analysis by Jafar-Mohammadi et al. 2011
Jafar-Mohammadi B et al. A role for coding functional variants in HNF4A in type 2 diabetes susceptibility. Diabetologia, 2011 combining data from 14,279 cases and 26,835 controls: OR 1.20 (95% CI 1.10–1.30), p=2.1×10⁻⁵. This is a modest but well-replicated effect. The original Japanese discovery cohort (Zhu 2003) found a larger OR of 4.3 in a smaller sample — the larger meta-analytic OR of 1.20 is the more reliable estimate.

Population-specific effects are notable. Granados-Silvestre et al. 2017⁴⁴ Granados-Silvestre et al. 2017
Granados-Silvestre MA et al. Susceptibility background for type 2 diabetes in eleven Mexican Indigenous populations: HNF4A gene analysis. Mol Genet Genomics, 2017 found the T allele at 2.7–16% in Mexican indigenous groups, with a consistent association with hypertriglyceridemia. The variant appears to have been positively selected in some Amerindian populations, possibly conferring metabolic advantage under historical nutritional stress while now contributing to T2D risk in a calorie-dense environment.

A pediatric metabolic syndrome association was documented by García-Rodríguez et al. 2020⁵⁵ García-Rodríguez et al. 2020
García-Rodríguez MH et al. Association of the T130I Variant of the HNF4A Gene with Metabolic Syndrome and Its Components in Mexican Children. Metab Syndr Relat Disord, 2020: OR 2.31 (95% CI 1.10–4.83, p=0.026) for metabolic syndrome in children, with abdominal obesity as the dominant component (OR 1.20). This is the earliest age at which T130I phenotypic consequences have been documented.

The Spanish family study by Cieza-Borrella et al. 2014⁶⁶ Cieza-Borrella et al. 2014
Cieza-Borrella C et al. Early-onset type 2 diabetes mellitus is associated to HNF4A T130I polymorphism in families of central Spain. J Investig Med, 2014 found that T130I carriers in diabetes families had significantly higher HbA1c and fasting glucose than non-carriers, with diabetes onset often triggered by stressful situations and tightly linked to gestational diabetes in female carriers.

Practical Actions

The key implication for T allele carriers is liver-centric metabolic monitoring: fasting lipid panel (particularly triglycerides and HDL), fasting glucose, and HbA1c. The hepatocyte-specific nature of the dysfunction means insulin secretion capacity is less impaired than in full MODY1 patients, but liver-driven insulin resistance and dyslipidemia accumulate over time. Reducing hepatic triglyceride burden — through dietary carbohydrate restriction and omega-3 fatty acids — directly addresses the HNF4A-driven lipid dysregulation pathway.

Homozygous TT carriers are extremely rare (~0.1%) and warrant additional vigilance: both alleles carry the partial loss-of-function, potentially doubling hepatic HNF4A impairment and compounding metabolic risk.

Interactions

HNF4A directly activates HNF1A transcription. Carriers who also have functional variants in HNF1A (rs1169288, Ile27Leu) or HNF1B may have compounded transcription factor cascade disruption. The T130I variant in HNF4A affects the DNA-binding domain, while the truly pathogenic MODY1 nonsense variants (rs137853334) eliminate transactivation entirely — these are mechanistically distinct and should not be conflated in clinical communication.